Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Q4 Revenues Grow 43 Percent to $47.5M

NEW YORK, Feb. 11 (GenomeWeb News) - Molecular Devices yesterday reported total revenues of $47.5 million for the fourth quarter ending Dec. 31, a 43-percent improvement over $33 million in revenues that the company posted for same quarter last year.


The company reported a one-time restructuring charge of $1.2 million for the acquisition of Axon Instruments and had net income of $14.6 million, compared to $3 million a year ago.


Molecular Devices' R&D spending increased 52 percent to $7 million in the quarter from $4.6 million in Q4 2003.


The Sunnyvale, Calif.-based company reported cash and cash equivalents of $30 million on the quarter and a non-operating gain of $18.3 million from the sale of company in which it had an equity investment.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.